The DNA mismatch repair (MMR) pathway recognizes and repairs errors in base pairing and acts to maintain genome stability. Cancers that have lost MMR function are common and comprise an important clinical subtype that is resistant to many standard of care chemotherapeutics such as cisplatin. We have identified a family of rhodium metalloinsertors that bind DNA mismatches with high specificity and are preferentially cytotoxic to MMR-deficient cells. Here, we characterize the cellular mechanism of action of the most potent and selective complex in this family, [Rh(chrysi)(phen)(PPO)]
The DNA mismatch repair (MMR) pathway recognizes and repairs errors in base pairing and acts to maintain genome stability. Cancers that have lost MMR function are common and comprise an important clinical subtype that is resistant to many standard of care chemotherapeutics such as cisplatin. We have identified a family of rhodium metalloinsertors that bind DNA mismatches with high specificity and are preferentially cytotoxic to MMR-deficient cells. Here, we characterize the cellular mechanism of action of the most potent and selective complex in this family, [Rh(chrysi)(phen)(PPO)]
2+
(Rh-PPO). We find that Rh-PPO binding induces a lesion that triggers the DNA damage response (DDR). DDR activation results in cellcycle blockade and inhibition of DNA replication and transcription. Significantly, the lesion induced by Rh-PPO is not repaired in MMRdeficient cells, resulting in selective cytotoxicity. The Rh-PPO mechanism is reminiscent of DNA repair enzymes that displace mismatched bases, and is differentiated from other DNA-targeted chemotherapeutics such as cisplatin by its potency, cellular mechanism, and selectivity for MMR-deficient cells.
cancer | DNA damage response | metalloinsertor | mismatch repair D NA mismatch repair (MMR) corrects mismatched base pairs that arise from replication errors and is involved in the recognition and processing of DNA damage induced by chemotherapeutics such as cis-diamminedichloroplatinum(II) (cisplatin) (1, 2) . Loss of function of the MMR pathway is an important mechanism for mutation generation and predisposition to cancer. Lynch syndrome, an inherited condition characterized by susceptibility to develop colon cancer, results from germline inactivation of the MMR pathway (3) . Somatic loss of function of the MMR pathway occurs in 10-25% of cancers of the colon, endometrium, ovary, and other tissue types (3) (4) (5) . MMR-deficient cancer cells display a 100-to 1,000-fold increase in mutation rate and are resistant to many DNA-targeted chemotherapeutics (6, 7) . Because of this, patients with MMR-deficient cancers do not benefit from standard of care therapy including cisplatin (8, 9) . New therapies that target these patient populations are needed.
We have previously described a class of octahedral rhodium(III) complexes, termed metalloinsertors, as a strategy toward the targeted therapy of MMR-deficient cancers. These compounds contain a sterically expansive 5,6-chrysenequinone diimine ligand (chrysi; Fig. 1A ) that binds with high specificity to DNA mismatches, independent of sequence context (10) . X-ray crystal structures demonstrate that the chrysi ligand is capable of inserting at the mismatch from the DNA minor groove; this binding mode, called metalloinsertion, maintains duplex stacking but displaces the mismatched bases into the major or minor groove (11, 12) . As a consequence, metalloinsertor binding preferentially inhibits DNA synthesis and growth of cell lines that are MMR-deficient (13) (14) (15) . Structureactivity relationship studies reveal that compound selectivity and cell potency are influenced by binding affinity, rate of compound diffusion into cells, and levels of compound accumulation in the cell nucleus relative to the mitochondria (14-16). These studies support the idea that cytotoxicity of the metalloinsertors results from targeting mismatches in the nuclear DNA.
One of the first-generation compounds, [Rh(HDPA) 2 chrysi]
3+
(Rh-HDPA; HDPA = 2,2′dipyridylamine), was shown to increase the percentage of cells in G2/M phase, leading to cell death by necrosis (15) . However, the poor cell potency of Rh-HDPA (EC 50 = 25 μM), coupled with just a twofold selectivity for MMR-deficient cells, limited cellular mechanism of action studies. Recently, newer-generation compounds with up to 100-fold improved cell potency over Rh-HDPA have been identified (17) . The most potent compound, [Rh(chrysi)(phen)(PPO)] 2+ [Rh-PPO; phen = 1,10-phenanthroline; PPO = 2-(pyridine-2-yl)propan-2-ol] (Fig. 1A) , also has increased selectivity for MMR-deficient cells (17) . The mechanism behind the increased cell potency and selectivity of Rh-PPO is not understood, as its binding affinity, specificity for mismatches, and cellular uptake characteristics are comparable to those of Rh-HDPA.
Rh-PPO and other newer-generation metalloinsertors contain an unusual ligand coordination. Where early iterations of complexes comprised an all-nitrogen coordination environment, the next-generation metalloinsertors contain an axial Rh-O bond (Fig.  1A) . This ligand coordination reduces the overall charge of the complex from [3 + ] to [2 + ], consequently raising the pK a of the chrysi imminium proton above biological pH. X-ray crystallographic analysis of these structures reveals that the fully protonated chrysi ligand adopts a buckled rather than planar conformation, which it retains when bound to DNA (17) . This binding mode may contribute to the potent cellular activity of the compounds.
Significance
We have developed a family of rhodium compounds that bind DNA mismatches and are cytotoxic to mismatch repair (MMR)-deficient cancer cells. This study describes the cellular mechanism of action of the compounds that enables this selective cytotoxicity. The compound binding mode, metalloinsertion, displaces the mismatched base pairs from the DNA helix and creates a DNA lesion that activates the DNA damage response. This lesion is unable to be repaired in MMR-deficient cells. This mechanism is distinct from other compounds that target DNA and provides a therapeutic strategy for treatment of cancers with MMR deficiency.
Here, we use Rh-PPO as a tool compound to investigate the cellular mechanism of action of the current generation of metalloinsertors. We find that Rh-PPO inhibits DNA transcription, in addition to DNA synthesis, and blocks cell-cycle progression. Rh-PPO activity induces DNA damage and activates the DNA damage response (DDR). DDR activation leads to cell death by a nonapoptotic mechanism, unlike other DNA-targeted chemotherapeutics such as cisplatin that induce apoptosis following DDR activation. We propose that Rh-PPO binding, and the resulting displacement of mismatched base pairs from the helix, creates a lesion that is recognized by the DDR pathway. This activity is reminiscent of certain DNA repair enzymes that flip out damaged base pairs upon binding (18) . However, in the case of Rh-PPO, DDR activation is not followed by repair in MMR-deficient cells, and we propose that Rh-PPO binding blocks processing of the mismatched base pairs by repair enzymes. As the mechanism by which metalloinsertors initiate their selective cytotoxic effects becomes increasingly clear, next-generation complexes with enhanced potency and selectivity represent a potential translational avenue for targeting MMRdeficient cancers.
Results
Rh-PPO Is Selectively Cytotoxic to MMR-Deficient Cells. Rh-PPO (Fig. 1A) was identified in structure-activity relationship studies of metalloinsertors with an axial Rh-O bond and was found to have nearly 100-fold increased cell potency relative to earlier-generation compounds (17) . To further characterize the cytotoxic activity of Rh-PPO, we carried out a dose-response assay in the matched colorectal cancer cell lines HCT-116 N (MMR-proficient) and HCT-116 O (MMR-deficient) (19) . After 72 h incubation, viable cells were counted using high-content imaging. Rh-PPO decreased cell viability in the MMR-deficient HCT-116 O cells with an EC 50 of 0.15 ± 0.06 μM (Fig. 1B) . The number of MMR-proficient HCT-116 N cells was affected only at 10-fold higher compound concentrations (EC 50 = 1.12 ± 0.27 μM) (Fig. 1B) . In time-lapse imaging studies, 0.5 μM Rh-PPO, a concentration above the cell EC 90 , blocked cell division of HCT-116 O cells within the first 24 h and induced cell swelling and bursting at later time points, consistent with cell death (Fig. 1C) . In contrast, the same concentration of Rh-PPO in HCT-116 N cells did not impact cell growth, and cells retained a normal morphology (Fig. 1C) . The growth rate of Rh-PPO-treated HCT-116 N cells was similar to that of untreated cells (Fig. S1 ).
The selective cytotoxicity of Rh-PPO for HCT-116 O cells extended to other MMR-deficient cancer cell lines. In an NCI-H23 lung cancer cell line engineered with an inducible shRNA to MLH1 (20), we found that Rh-PPO inhibited viability of cells that had downregulated MLH1 with an EC 50 of 0.39 ± 0.07 μM, whereas the MLH1-expressing cells had an EC 50 of 2.6 ± 0.33 μM (Fig. S2) . In a panel of nonmatched ovarian cancer cell lines, Rh-PPO also preferentially induced cytotoxicity of MMR-deficient cells (average EC 50 of 0.07 μM; range 0.06-0.10 μM) compared with MMR-proficient cells (average EC 50 of 0.23 μM; range 0.10-0.26 μM) (Fig. S3 ). These findings demonstrate that Rh-PPO has broad activity against MMRdeficient cells and suggest that the phenotype of MMR deficiency, rather than loss of function of a specific MMR protein such as MLH1 or MSH2, is critical for the metalloinsertor selectivity.
The selectivity of Rh-PPO for MMR-deficient cells is opposite to that of cisplatin, a DNA-targeted chemotherapeutic which creates intrastrand cross-links and adducts that are preferentially cytotoxic toward MMR-proficient cells. Cisplatin decreased cell viability in HCT-116 O cells with an EC 50 of 3.98 ± 0.21 μM, and in HCT-116 N cells with an EC 50 of 1.45 ± 0.09 μM, after a 72-h incubation (Fig. 1B) . In time-lapse imaging studies, cells treated with 5 μM cisplatin, a concentration over the cell EC 90 , initially continued to grow and divide and exhibited an increased cell size before undergoing cell death (Fig. 1C ). Rh-PPO is both more potent and more selective than cisplatin for MMR-deficient cells, and appears to act by a different mechanism than cisplatin.
Rh-PPO Inhibits Transcription. Metalloinsertor binding to a DNA mismatch might directly or indirectly block chromosomal processes such as DNA replication, transcription, or DNA repair. As part of the initial characterization of Rh-PPO, we found that incorporation of bromodeoxyuridine, a marker for DNA synthesis, was inhibited 62% more in MMR-deficient HCT-116 O cells compared with HCT-116 N cells (17) . To test whether Rh-PPO also inhibits transcription, we used high-content imaging to evaluate incorporation of the modified nucleotide ethynyl uridine (EU) into newly synthesized RNA. A 24-h treatment with Rh-PPO efficiently inhibited EU uptake in the MMR-deficient HCT-116 O cells, with an EC 50 of 0.09 ± 0.02 μM (Fig. 2A) . EU uptake in HCT-116 N cells was inhibited only at much higher concentrations of Rh-PPO (EC 50 = 0.81 ± 0.18 μM; Fig. 2A ). At 0.5 μM Rh-PPO, a concentration over the cell EC 90 , EU incorporation was inhibited in most HCT-116 O cells, whereas EU uptake in HCT-116 N cells was similar to that in cells that were not treated with compound (Fig. 2B) . Comparable results were obtained using an ELISA readout (Fig. S4) . Rh-PPO therefore selectively inhibits transcription in MMR-deficient cells.
Cisplatin inhibited transcription in both HCT-116 O and HCT-116 N cells, with preferential effects on the MMR-proficient cells. At a 5 μM concentration, EU incorporation was below the level of detection in 23.8% of HCT-116 O cells and 39.4% of HCT-116 N cells (Fig. 2 A and B) . Rh-PPO Activates the DDR. Metalloinsertor binding at a DNA mismatch displaces the mismatched base pairs from the helix stack into the major or minor groove (11, 12) . Whereas this binding mode may present a physical block to DNA unwinding, we also considered whether the displaced base pairs may be recognized as a lesion by cell surveillance checkpoints. We first evaluated phosphorylated histone H2AX (pH2AX), an early marker for activation of the DDR that correlates with the presence of DNA double-strand breaks (DSBs) in the cell nucleus (21) . Treatment with Rh-PPO increased the percentage of pH2AX-positive cells at 24 h preferentially in HCT-116 O cells (Fig. 3A) . In the presence of 0.5 μM Rh-PPO, 50.8 ± 1.2% of HCT-116 O cells were positive for pH2AX, and just 11.5 ± 0.7% of HCT-116 N cells were positive for pH2AX (Fig. 3 A and B) . As a comparison, we examined pH2AX induction in cells treated with cisplatin, which generates DSBs as a consequence of the processing of intrastrand crosslinks. The cisplatin-treated cells displayed high levels of pH2AX staining at 24 h, notably with opposite selectivity to Rh-PPO (Fig.  3A) . With 5 μM cisplatin treatment, 38.2 ± 5.4% HCT-116 O cells, compared with 69.6 ± 1.7% HCT-116 N cells, were pH2AX-positive ( Fig. 3 A and B) . Untreated HCT-116 O and HCT-116 N cells contained a low percentage of pH2AX-positive cells (Fig.  3B) , consistent with occasional, spontaneous DNA damage that occurs during DNA replication (22) .
The initial damage signal induced by Rh-PPO was amplified by phosphorylation of the checkpoint protein kinase Chk1, a transducer of the DDR signal that is associated with regions of singlestranded DNA (23) . After 24 h treatment with 0.5 μM Rh-PPO, 59.2 ± 0.9% of HCT-116 O cells contained nuclear, phosphorylated Chk1 (pChk1), and 20 ± 1.3% of HCT-116 N cells displayed pChk1 (Fig. S5) . Cisplatin also increased Chk1 phosphorylation, with 46.9 ± 11.9% of HCT-116 O cells and 72.3 ± 1.7% of HCT-116 N cells exhibiting pChk1 staining after 24 h treatment with 5 μM cisplatin (Fig. S5) . Together, these data suggest that Rh-PPO binding generates an aberrant structure that is recognized as a lesion by the DDR. The striking difference in selectivity of Rh-PPO compared with cisplatin suggests that requirements for processing of their respective lesions are completely distinct.
The Rh-PPO Lesion Generates DNA Damage but Does Not Activate Apoptosis. Normally, activation of the DDR would trigger repair of a DNA lesion or lead to apoptosis if the DNA damage is severe.
To understand more about the nature of the lesion generated by Rh-PPO, we first examined cellular levels of reactive oxygen species (ROS), which are a potential source of DNA DSBs. At 0.5 μM Rh-PPO, a concentration above the cell EC 90 that was sufficient to induce DDR activation and cell death, ROS levels were only increased slightly, to levels 1.5× that of untreated cells after 72 h (Fig.  4A ). We used a Comet assay to assess damage to nuclear DNA such as DSBs and single-strand breaks. After 24 h treatment with 0.5 μM of Rh-PPO, 64.0 ± 4.0% of HCT-116 O nuclei displayed Comet tails indicating the presence of fragmented DNA, whereas just 27.0 ± 7.0% of HCT-116 N nuclei generated Comet tails (Fig.  4B) . Background levels of DNA damage in untreated HCT-116 O and HCT-116 N cells were 18.4 ± 4.0%. The damage caused by Rh-PPO may be distinct from that generated by cisplatin, which caused an increase in both ROS levels and fragmented DNA, with a stronger effect observed in the MMR-proficient HCT-116 N cells: 51.0 ± 1.5% of HCT-116 N nuclei displayed Comet tails versus 32.0 ± 10.0% of HCT-116 O nuclei (Fig. 4B) .
The lesion generated by Rh-PPO occurred within the first cell cycle. Rh-PPO blocked cell-cycle progression of HCT-116 O cells within 24 h (Fig. 1C) . This is consistent with our initial observation that metalloinsertor treatment led to an accumulation of cells in the G2/M phase (17) . Interestingly, the cell death triggered by Rh-PPO occurred primarily by a nonapoptotic pathway, and the activity of caspases 3 and 7 was not increased (Fig. 4C) . In addition, cells treated with 0.5 μM Rh-PPO did not exhibit nuclear fragmentation characteristic of apoptotic cells (Fig. 4D) .
The cell morphology resulting from Rh-PPO treatment is distinct from that of cisplatin. Cells treated with cisplatin did not appear to arrest in the first cell cycle, but rather continued to grow and divide, generating fragmented nuclei by 72 h (Fig. 4D) . Consistent with this observation, 5 μM cisplatin efficiently induced caspase activation (Fig. 4C) . Together, these data support a model in which Rh-PPO generates a lesion that is processed in a completely different way than cisplatin and thus enables selective cytotoxicity against MMR-deficient cells (Fig. 5) .
Discussion
In this study we describe the mechanism of action of Rh-PPO, a new-generation metalloinsertor with high cell potency and selectivity for MMR-deficient cancer cells. Rh-PPO inserts from the DNA minor groove at thermodynamically destabilized mismatch sites, and the resulting displacement of the mismatched bases from the helical stack generates a lesion that activates the DDR and leads irreversibly to nonapoptotic cell death. We propose that the selectivity of Rh-PPO is driven by its binding to DNA mismatches in the cell nucleus, which occur at up to 1,000-fold higher levels in MMR-deficient cells relative to MMRproficient cells (6, 7) . We propose that the high cell potency of Rh-PPO derives from the buckled orientation of the chrysi ligand in the DNA minor groove, which gives distinct positioning and potentially increased extrusion of the mismatched base pairs compared with earlier generation metalloinsertors; other characteristics of the metal complexes, including binding affinity and cellular uptake, are similar (17) .
The lesion generated by Rh-PPO binding is clearly different from that generated by cisplatin. Cisplatin binding to DNA primarily forms intrastrand cross-links, such as 1,2-intrastrand d(GpG) adducts, that are converted to DSBs as cells progress through S phase, leading to activation of the DNA damage response and apoptosis (24) (25) (26) . Cisplatin preferentially targets MMR-proficient cells, in part due to the role of MMR proteins in recognition and processing of the lesions (1, 2) . Insight into the differences between metalloinsertors and platinum complexes can also be drawn from analysis of bimetallic rhodium-platinum complexes (27, 28) . A conjugate of cisplatin to one of the newer-generation metalloinsertors, [Rh(chrysi)(phen)(DPE)] 2+ [DPE = 1,1-di(pyridine-2-yl)ethanol], bound DNA both noncovalently through metalloinsertion at a mismatch and covalently through platinum binding at N3-adenine in the minor groove (28) . This bimetallic complex preferentially targeted mismatched DNA and showed improved cell potency relative to cisplatin, but the complex lost specificity for MMRdeficient cancer cells and induced cell death primarily by apoptosis, not unlike cisplatin (28) . This result suggests that the covalent linkage of cisplatin to DNA dominates the cellular response to the bimetallic complexes.
Rh-PPO is also distinct from other compounds that are reported to preferentially target MMR-deficient cells. Cytosine-based nucleoside analogs such as cytarabine generate high levels of ROS and are proposed to preferentially induce apoptosis in MMR-deficient cells by destabilizing the membrane potential of mitochondria (29) . Triamterene, a diuretic drug, increases ROS and induces apoptosis through a mechanism that requires thymidine synthase activity (30) . Coincubation with folates abolishes the cytotoxic activity of triamterene against MMR-deficient cells (30) , suggesting that in vivo, cancer cells may be able to develop resistance to this drug.
The Rh-PPO mechanism is reminiscent of lesion-specific DNA glycosylases that probe destabilized regions of the genome and, upon binding, flip the mismatched base into the enzyme active site (31, 32) . Indeed, the first-generation metalloinsertor, similar to a glycosylase, was able to photochemically cleave DNA at a mismatch site (31, 33) . A mismatch bound by a glycosylase typically would undergo further processing such as base excision and repair (18) . However, in the case of Rh-PPO, we propose that metalloinsertor binding blocks access of DNA repair enzymes to the lesion. A mismatch-specific glycosylase might not be able to recognize mismatched bases that have already been ejected from the stacked helix. Alternatively, it is possible that the lesion generated by metalloinsertor binding requires MMR proteins for repair. The cell death that follows Rh-PPO binding is unusual in that it is primarily nonapoptotic. It may be that the unusual nature of the Rh-PPO lesion fails to be recognized by the apoptotic machinery. Alternatively, cells may default to necrosis because signaling by the DDR is unproductive; a similar mechanism was proposed for taxanes, which trigger prolonged signaling of the spindle microtubule assembly checkpoint leading eventually to nonapoptotic cell death (34) . Our current efforts are focused on defining a highresolution crystal structure of the Rh-PPO/DNA complex and exploring the kinetics of association of DNA repair proteins with the displaced bases.
Until recently, therapeutic options for treatment of MMR-deficient cancers have been limited. Chemotherapy has been the standard of care despite lack of evidence for benefit with this treatment (8, 9) . Prospective testing for MMR deficiency has mainly been limited to colorectal cancer (35) . The mechanism of action that we demonstrate for Rh-PPO offers the possibility of therapeutic strategies targeted specifically to cancers associated with deficiencies in MMR.
Materials and Methods
Compounds. Rh-PPO was synthesized as described previously (17) . Compound concentration was calculated by UV/Vis spectroscopy based on the previously reported extinction coefficient (17) . Cisplatin was obtained from Sigma. Rh-PPO and cisplatin were dissolved in Milli-Q water and stored at room temperature in the dark. (19) . HCT-116 O and HCT-116 N cells were also engineered to stably express histone H2B-green fluorescent protein (H2B-GFP). Histone H2B-GFP from the pBOS-H2B-GFP vector (Becton Dickinson) was subcloned into the SalI/ NotI restriction sites of the pENTR vector (Life Technologies), and then moved into the Gateway-compatible lentiviral vector pLV418G (36) . The construct was packaged into lentivirus which was used to transduce cells. Cells that had stably integrated histone H2B-GFP into the chromosome were selected with zeocin and expanded.
Cells were grown and maintained in Roswell Park Memorial Institute (RPMI) media that contained 10% FBS, 1% penicillin/streptomycin, 1× nonessential amino acids, 1 mM sodium pyruvate, and 1 mM L-glutamine, to which 400 μg/mL geneticin (Gibco) was added. Cells were maintained at 37°C with 5% CO 2 .
Cell Assays. Cells were plated to 96-well View Plates (Perkin-Elmer) and allowed to adhere overnight. Cells were then treated with compounds in a dose-response for 24-72 h. The treated cells were assayed directly, as described below, or were fixed in 4% formaldehyde and permeabilized with 0.5% Triton X-100 in PBS before antibody staining for indirect immunofluorescence. Cells were blocked in 1× blocking buffer (Thermo Fisher), and incubated with primary antibody at 1:100 overnight at 4°C. Cells were then washed in PBS and incubated with secondary antibody and 4′,6-diamidino-2-phenylindole (DAPI; Sigma) at 1:1,000. High-content imaging (Cellomics ArrayScan, Thermo Fisher) was used to collect and analyze images as well as for cell viability based on nuclear count.
Extrusion of Mismatched Bases

DNA Damage Response
Cell Cycle Block Non-Apoptotic Cell Death DNA transcription was evaluated with Click-It assays for 5-EU uptake, performed according to the manufacturer's protocol (Thermo Fisher). Cells were pulse labeled with EU for 1 h before processing for antibody staining. Activation of the DDR was evaluated by indirect immunofluorescence, using primary antibodies against pH2AX and pChk1 (Cell Signaling). Secondary antibodies conjugated to Alexa Fluor 488 or Alexa Fluor 594 were from Thermo Fisher. Cell nuclei were stained with DAPI. Cell viability was independently assessed using Cell Titer-glo assays (Promega).
For live cell imaging studies, cells were plated to 35-mm dishes (MatTek) that were precoated with rat collagen (Becton Dickinson). Just before imaging, fresh media and compound were added to the cells. Differential interference contrast (DIC) and GFP images were collected every 4 h using a 540L Zeiss confocal microscope; data were analyzed with Zen software (Zeiss).
Cellular ROS levels were assessed with a 2′,7′-dichlorofluorescein diacetate (DCFDA)-reactive oxygen species detection assay (Abcam). Cells were plated to Perkin-Elmer View plates, and then were treated with DCFDA for 1 h before Rh-PPO or cisplatin were added in a dose-response for a total of 24 h. The fluorescent compound 2′, 7′-dichlorofluorescein (DCF), a product of DCFDA oxidation, was measured using a Tecan Safire2 microplate reader.
DNA damage was evaluated using a Comet assay (Cell Biolabs). Cells were treated with compound as indicated, and then collected using a cell scraper, mixed with melted agarose, and pipetted onto slides. The samples were denatured and then analyzed by Tris/borate/EDTA gel electrophoresis at 35 V for 20 min to separate DNA fragments from intact DNA. The samples were then stained with a fluorescent dye to visualize the cellular DNA, and imaged using an EVOS cell-imaging system (Thermo Fisher).
Cell apoptosis was evaluated using a Caspase 3/7 Glo assay kit (Promega). Cells treated with Rh-PPO or cisplatin in a dose-response for 24 h were incubated with a substrate that luminesces upon cleavage by caspases. Luminescence was measured using an Envision plate reader (Perkin-Elmer).
All cellular assays were performed at least three times with duplicate samples. Data were analyzed in Graph Pad (Prism). Statistical analysis was carried out using the two-tailed Student's t test, using mean and SE values from three or more independent experiments. For the high content imaging studies, 9 fields per well were collected at 20× magnification (>1,000 cells per sample, with duplicate samples).
